A randomized, double-blind, placebo-controlled phase I trial of inhalation treatment of recombinant TFF2-IFN protein: A multifunctional candidate for the treatment of COVID-19

A randomized, double-blind, placebo-controlled phase I trial of inhalation treatment of recombinant TFF2-IFN protein: A multifunctional candidate for the treatment of COVID-19

Background and Objectives: Coronavirus disease 2019 (COVID-19) has caused global pandemics in the last 3 years, and the development of new therapeutics is urgently needed. This study aimed to assess the safety, tolerated, and prolonged retention of recombinant protein trefoil factor 2 (TFF2)- interf...

Full description

Bibliographic Details
Main Authors: Yan Liu, Guanxing Zhai, Weihui Fu, Xiaoyan Zhang, Jianqing Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Pharmacology
Subjects:
respiratory viral infection
COVID-19
IFN
TFF2
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1063106/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1063106/full

Similar Items